Noninvasive vascular therapy
First Claim
1. A method for destroying or impairing target cells that comprise a lesion in the vascular system in a mammalian subject comprising:
- administering to the subject a therapeutically effective amount of a photosensitizing agent, wherein said photosensitizing agent selectively binds to target cells of the lesion;
irradiating at least a portion of the subject with light at a wavelength absorbed by said photosensitizing agent, wherein said light is provided by a light source that is external to the intact body of the subject; and
wherein said irradiation is at a relatively low fluence rate that results in the activation of said photosensitizing agent or said prodrug product wherein said PDT drug is cleared from the skin and subcutaneous tissues of the subject prior to said irradiation.
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention is drawn to methods and compounds for transcutaneous photodynamic therapy (“PDT”) of a target tissue or compositions in a mammalian subject, which includes administering to the subject a therapeutically effective amount of a photosensitizing agent or a photosensitizing agent delivery system or a prodrug where the photosensitizing agent or photosensitizing agent delivery system or prodrug selectively binds to the target tissue; and irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent or if prodrug, by a prodrug product thereof where the light is provided by a light source, and where the irradiation is at low fluence rate that results in the activation of the photosensitizing agent or prodrug product. These methods of transcutaneous PDT are useful in the treatment of specifically selected target tissues, such as: vascular endothelial tissue abnormal vascular wall of tumors; tumors of the head and neck; tumors of the gastrointestinal tract; tumors of the liver; tumors of the esophopharyngeal; tumors of the lung; lymphoid tissue; lesions in the vascular system; hone marrow and tissue related to autoimmune disease.
-
Citations
24 Claims
-
1. A method for destroying or impairing target cells that comprise a lesion in the vascular system in a mammalian subject comprising:
-
administering to the subject a therapeutically effective amount of a photosensitizing agent, wherein said photosensitizing agent selectively binds to target cells of the lesion;
irradiating at least a portion of the subject with light at a wavelength absorbed by said photosensitizing agent, wherein said light is provided by a light source that is external to the intact body of the subject; and
wherein said irradiation is at a relatively low fluence rate that results in the activation of said photosensitizing agent or said prodrug productwherein said PDT drug is cleared from the skin and subcutaneous tissues of the subject prior to said irradiation. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21)
-
-
2. A method for destroying or impairing target cells that comprise a lesion in the arterial vascular system in a mammalian subject comprising:
-
administering to the subject a therapeutically effective amount of a first conjugate comprising a first member of a ligand-receptor binding pair conjugated to an antibody or antibody fragment, wherein said antibody or antibody fragment selectively binds to a target cell or target tissue antigen;
administering to the subject a therapeutically effective amount of a second conjugate comprising a second member of the ligand-receptor binding pair conjugated to a photosensitizing agent or photosensitizing agent delivery system or prodrug, wherein the first member binds to the second member of the ligand-receptor binding pair;
irradiating at least a portion of the subject with light at a wavelength absorbed by said photosensitizing agent, wherein said light is provided by a light source that is external to the subject; and
wherein said irradiation is at a relatively low fluence rate that results in the activation of said photosensitizing agent or prodrug product. - View Dependent Claims (15, 16)
-
-
22. An apparatus for transcutaneous photodynamic therapy of a lesion in the vascular system in a mammalian subject comprising a light source that is external to the subject and is selected from the group consisting of one or a plurality of:
- laser diodes;
light emitting diodes;
electroluminescent light sources;
incandescent light sources;
cold cathode fluorescent light sources;
organic polymer light sources;
or inorganic light sources. - View Dependent Claims (23, 24)
- laser diodes;
Specification